About this item:

69 Views | 50 Downloads

Author Notes:

Cheryl L. Maier, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, 101 Woodruff Circle Room 2339, Atlanta, GA 30322, USA. cheryl.maier@emory.edu

Alexander D. Truong, Sara C. Auld, Nicholas A. Barker, Sarah Friend, A. Thanushi Wynn, Jason Cobb, Roman M. Sniecinski, Christin‐Lauren Tanksley, Derek M. Polly, Manila Gaddh, Michael Connor, Hirotomo Nakahara, H. Clifford Sullivan, Christine Kempton, and Cheryl L. Maier designed and executed this work. Alexander D. Truong, Sara C. Auld, Nicholas A. Barker, Sarah Friend, A. Thanushi Wynn, Jason Cobb, and Christin‐Lauren Tanksley collected data. Cheryl L. Maier, Roman M. Sniecinski, Jeannette Guarner, Alexander Duncan, Cassandra D. Josephson, Sean R. Stowell and John D. Roback analyzed data. Alexander D. Truong, Sara C. Auld, Sean R. Stowell and Cheryl L. Maier wrote the initial draft, which was commented on and edited by all authors.

The authors wish to thank Dr. Lisa Daniels for her astute clinical observations that aided in the presentation of this series, as well as Melanie Sherman, Stacian Reynolds, and the clinical immunology staff for viscometry testing, and the hemapheresis nurses for their dedication in caring for these patients.

All of the authors have no conflicts to disclose.

Subjects:

Research Funding:

SCA is supported by NIH/NIAID K23 AI134182; CLM is supported by NIH/NHLBI K99 HL150626‐01.

Therapeutic plasma exchange for COVID‐19‐associated hyperviscosity

Show all authors Show less authors

Tools:

Journal Title:

TRANSFUSION

Volume:

Volume 61, Number 4

Publisher:

, Pages 1029-1034

Type of Work:

Article | Final Publisher PDF

Abstract:

Background Recent data suggests an association between blood hyperviscosity and both propensity for thrombosis and disease severity in patients with COVID‐19. This raises the possibility that increased viscosity may contribute to endothelial damage and multiorgan failure in COVID‐19, and that therapeutic plasma exchange (TPE) to decrease viscosity may improve patient outcomes. Here we sought to share our experience using TPE in the first 6 patients treated for COVID‐19‐associated hyperviscosity. Study Design and Methods Six critically ill COVID‐19 patients with plasma viscosity levels ranging from 2.6 to 4.2 centipoise (cP; normal range, 1.4‐1.8 cP) underwent daily TPE for 2‐3 treatments. Results TPE decreased plasma viscosity in all six patients (Pre‐TPE median 3.75 cP, range 2.6‐4.2 cP; Post‐TPE median 1.6 cP, range 1.5‐1.9 cP). TPE also decreased fibrinogen levels in all five patients for whom results were available (Pre‐TPE median 739 mg/dL, range 601‐1188 mg/dL; Post‐TPE median 359 mg/dL, range 235‐461 mg/dL); D‐dimer levels in all six patients (Pre‐TPE median 5921 ng/mL, range 1134‐60 000 ng/mL; Post‐TPE median 4893 ng/mL, range 620‐7518 ng/mL); and CRP levels in five of six patients (Pre‐TPE median 292 mg/L, range 136‐329 mg/L; Post‐TPE median 84 mg/L, range 31‐211 mg/L). While the two sickest patients died, significant improvement in clinical status was observed in four of six patients shortly after TPE. Conclusions This series demonstrates the utility of TPE to rapidly correct increased blood viscosity in patients with COVID‐19‐associated hyperviscosity. Large randomized trials are needed to determine whether TPE may improve clinical outcomes for patients with COVID‐19.

Copyright information:

© 2020 AABB

Export to EndNote